Gregory Zante
Fortune : 6 M $ au 31/05/2026
Fortune : 6 M $ au 31/05/2026
Gregory S.
Zante is Chief Financial & Accounting Officer at Viking Therapeutics, Inc. since 2021.
Formerly, Mr. Zante was Chief Financial Officer at Aerami Therapeutics, Inc. from 2013 to 2016, Vice President-Finance & Administration at Sangamo Therapeutics, Inc. from 2003 to 2013, Director-Finance & Administration at Calyx Therapeutics, Inc. from 2001 to 2003, Senior Vice President at Matrix Pharmaceutical, Inc. from 1995 to 2001, and Senior Staff Accountant at Ernst & Young LLP from 1993 to 1995.
Mr. Zante completed undergraduate studies at the University of California, Los Angeles.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/03/2026 | 185 538 ( 0,16 % ) | 6 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| VIKING THERAPEUTICS, INC. | Directeur Financier/CFO | 04/01/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
Aerami Therapeutics, Inc.
Aerami Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops inhaled insulin products to treat diabetes patients | Directeur Financier/CFO | 01/01/2016 |
| SANGAMO THERAPEUTICS, INC. | Directeur Administratif | 01/06/2013 |
Calyx Therapeutics, Inc.
Calyx Therapeutics, Inc. Medical/Nursing ServicesHealth Services Provides therapies services for diabetes and inflammatory diseases | Directeur Financier/CFO | - |
Matrix Pharmaceutical, Inc.
Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Researches and develops pharmaceutical products | Corporate Officer/Principal | 01/12/2001 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Corporate Officer/Principal | 01/11/1995 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 7 |
|---|---|
Matrix Pharmaceutical, Inc.
Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Researches and develops pharmaceutical products | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Commercial Services |
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Calyx Therapeutics, Inc.
Calyx Therapeutics, Inc. Medical/Nursing ServicesHealth Services Provides therapies services for diabetes and inflammatory diseases | Health Services |
Aerami Therapeutics, Inc.
Aerami Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops inhaled insulin products to treat diabetes patients | Health Technology |
Viking Therapeutics, Inc.
Viking Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for metabolic and endocrine disorders | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national